Cure8

Why This Matters

If EPS helps restrain inflammation by shifting macrophages toward an M2 phenotype and is reduced in active UC, it could help explain mechanisms of mucosal inflammation and point to new biomarker or therapeutic strategies relevant to people with UC.

Who Should Pay Attention

Researchers studying immune regulation, macrophage biology, and the gut microbiome; clinicians interested in translational UC research; patients and advocates following emerging biomarker or therapeutic targets for ulcerative colitis.

Study Snapshot

Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract

What To Know

This paper (abstract) reports that loss of the long intergenic non-coding RNA lincRNA‑EPS worsened colitis in a mouse DSS model and was associated with more inflammation, disrupted tight junction proteins, and altered gut microbiota.

The authors show EPS modulates macrophage polarization by reducing pro‑inflammatory M1 and promoting anti‑inflammatory M2 states in vitro and in vivo, and report lower EPS expression in inflamed colon biopsies and PBMCs from people with ulcerative colitis, correlating with disease activity.

The study combines mouse genetic knockout experiments, cellular assays (qRT‑PCR, flow cytometry, immunofluorescence), microbiome assessment, and human biopsy/PBMC measurements. Findings suggest EPS plays an immune‑regulatory role that links macrophage polarization and microbiota in UC and could be explored as a therapeutic target or biomarker.

This brief is based on the article abstract provided by Frontiers in Immunology (structured content depth: abstract); Cure8 has not reviewed the full paper beyond the supplied text.

Keep In Mind

This summary is grounded in the journal abstract. Mouse DSS models and cell assays suggest mechanisms but do not prove efficacy in humans. The article reports decreased EPS in human UC samples, but clinical utility as a biomarker or therapy requires further validation and clinical studies.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationFrontiers in Immunology
PublisherFrontiers Media SA
AuthorsFengqin Zhu, Guiyuan Jin, Lihao Shi +5 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedSep 15, 2026, 12:00 AM
Content availableJournal abstract

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →